| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 12, 2024 | Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates | USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to impro... |
| Aug 1, 2024 | Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights | Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer
On track to report overall survival results from randomized BRACELET-1 breast can... |
| May 9, 2024 | Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer | US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study
Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program
First patient expected to... |
| May 9, 2024 | Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights | Pelareorep advancing to registration-enabling studies
Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer
Overall survival data from BRACELET-1 breast cancer study ... |
| Mar 7, 2024 | Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Impressive objective response rate in GOBLET study anal carcinoma coh... |
| Feb 2, 2022 | Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer | PALM BEACH, Fla., Feb. 2, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials offer patients early access to ... |
| Jan 24, 2022 | Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential | VANCOUVER, BC, Jan. 24, 2022 /PRNewswire/ -- USA News Group - Within the grand battle against cancer, the use of immunotherapy continues to grow at incredible rates. According to Precedence Research, the global cancer immunotherapy market i... |
| Jan 20, 2022 | Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Cli... |
| Jan 20, 2022 | Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical O... |
| Jan 20, 2022 | Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins
Company moving to full enrollment pending independent safety review
Multi-center trial being conducted in collaboration with Roche an... |
| Jan 11, 2022 | Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook | SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
To the Shareholders of Oncolytics Biotech,
2021 generated ground-brea... |
| Dec 21, 2021 | Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer | - Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations
SAN DIEGO and CALGARY, AB, Dec. 21, 2021 /PRNewswir... |
| Dec 13, 2021 | Artificial Intelligence Being Used To Accurately Predict Synergistic Cancer Drug Combinations | FN Media Group Presents USA News Group News Commentary
Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel artificial intelligence (AI) framework to make predictions on potential synergistic anti-ca... |
| Dec 10, 2021 | Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy | PALM BEACH, Fla., Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provis... |
| Nov 3, 2021 | Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers | Multi-center trial is being conducted in collaboration with Roche and AIO
Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer indications
Trial builds ... |
| Sep 20, 2021 | Oncolytics Biotech : reg; Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy | SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy i... |
| Sep 20, 2021 | Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 | FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., Sept. 20, 2021 /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development... |
| Sep 20, 2021 | Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 | PALM BEACH, Fla., Sept. 20, 2021 /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cost, and easy-... |
| Aug 6, 2021 | Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results | |
| Aug 6, 2021 | Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results | - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer
- Phase 2 BRACELET-1 (br... |
| Jul 5, 2021 | Oncolytics Biotech : reg; Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical... |
| May 20, 2021 | Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer | - The study achieved a 42% disease control rate in difficult-to-treat, second-line pancreatic cancer patients despite the absence of chemotherapy in the treatment regimen
- Pelareorep and pembrolizumab synergize to generate anti-cancer immu... |
| May 20, 2021 | Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer | SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination ... |
| May 20, 2021 | Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer | SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combi... |
| May 13, 2021 | Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference | Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET
SAN DIEGO and CALGARY, AB, May 13, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat ... |
| May 13, 2021 | Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference | Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET
SAN DIEGO and CALGARY, AB, May 13, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual firesid... |
| May 7, 2021 | ONCOLYTICS BIOTECH INC.
Oncolytics Biotech : reg; Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical... |
| May 7, 2021 | Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical... |
| May 7, 2021 | Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results | |
| May 3, 2021 | Oncolytics Biotech : Financial Report FY 2020 | Financial Statements and Management's
Discussion and Analysis
December 31, 2020
Oncolytics Biotech Inc.
TSX: ONC
Nasdaq: ONCY
MANAGEMENT DISCUSSION & ANALYSIS
2020
March 4, 2021
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITIO... |
| Apr 30, 2021 | ONCOLYTICS BIOTECH INC.
Oncolytics Biotech : reg; Announces Annual General Meeting | Management will also provide its annual corporate update after the conclusion of the meeting
SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") tod... |
| Apr 30, 2021 | Oncolytics Biotech® Announces Annual General Meeting | |
| Apr 29, 2021 | Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting | |
| Apr 12, 2021 | Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting | SAN DIEGO and CALGARY, AB, April 12, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The data a... |
| Apr 12, 2021 | Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting | - Pelareorep enhances anti-tumor efficacy of PARP-1 and CDK 4/6 inhibitors in preclinical models through a novel immunological mechanism not typically associated with PARP-1 and CDK 4/6 inhibitors
- Pelareorep synergizes with a broad array ... |
| Apr 12, 2021 | Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting | SAN DIEGO and CALGARY, AB, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The... |
| Apr 8, 2021 | Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference | SAN DIEGO and CALGARY, Alberta, April 8, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel discussion... |
| Apr 8, 2021 | Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference | SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel dis... |
| Apr 5, 2021 | Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors | SAN DIEGO and CALGARY, AB, April 5, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep i... |
| Apr 5, 2021 | Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors | Webinar will take place Monday April 12, 2021 at 2:00 pm ET
SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar dis... |
| Apr 5, 2021 | Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors | SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelar... |
| Mar 10, 2021 | Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting | |
| Mar 6, 2021 | ONCOLYTICS BIOTECH INC.
Oncolytics Biotech : Financial Report FY 2020 | Financial Statements and Management's
Discussion and Analysis
December 31, 2020
Oncolytics Biotech Inc.
TSX: ONC
Nasdaq: ONCY
MANAGEMENT DISCUSSION & ANALYSIS
2020
March 4, 2021
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITIO... |
| Mar 5, 2021 | Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights | |
| Nov 11, 2020 | Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results | |
| Jun 5, 2019 | Deerfield strikes up new deal with Columbia University; Ovid CEO Jeremy Levin joins BIO as new board chair | → In its latest deal, healthcare investment firm Deerfield Management and Columbia University have collaborated to launch Hudson Heights Innovations “to catalyze the development of novel therapeutics out of the r... |
